Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)

Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients with breast cancer (BC). Methods PALLAS is an open,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-10-01
Serie:	Breast Cancer Research
Soggetti:	Breast cancer HER2-low Palbociclib Endocrine therapy Antibody–drug conjugates
Accesso online:	https://doi.org/10.1186/s13058-024-01899-2
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!